FMP
Financial data for every need
We provide one of the most accurate financial data available on the market. You can get historical prices, fundamental data, insider transactions, and much more that goes back 30 years in history.
Get started
70,000+ Stocks with tons of data
Ready to Unlock Insights?
Welcome to our comprehensive suite of tools designed to streamline your financial data integration process.
API Documentation
Access user-friendly RESTful API documentation suitable for all skill levels.
Detailed endpoint documentation.
Clear request/response examples.
Streamlined navigation.
Ensures clarity/reliability.
API Viewer
Explore endpoints hassle-free with our code-free API Playground.
Interactive data tools.
User-friendly interface.
Download data in CSV/Excel.
Ideal for hands-on exploration.
Stock Prices
Real-time Prices, Historical Data and Indicators.
Stock Fundamentals
Financial Statements, Key Metrics, Stock Financial Scores and more.
Market News
Stock News, Press Releases and Experts Articles.
Company Information
Company Outlook, Market Capitalization, Company Core Information.
Data is collected only from trusted sources
Quality data is key to making accurate, informed decisions. All our data is licensed and sourced from curated third-party data partners, such as the U.S. Securities and Exchange Commission (SEC), Board of Governors of the Federal Reserve System.
See DocumentationFast, accurate, and developer friendly
We provide one of the most accurate data available on the market. We spent years designing endpoints and made them informative, well-documented, and easy to use.
Our API has over 100 endpoints and we are still growing and adding new endpoints every week. Every endpoint is available in JSON format and most of them also in CSV format.
We also provide on demand custom endpoint available for our enterprise plan.
See documentationTrusted by 100,000+ customers
Join us and get your API key
Latest News
Stay Updated and Harness the Power of Our API with the Latest News!
May 8, 2025 4:40 PM - Davit Kirakosyan
Krispy Kreme Shares Plunge 25% on Q1 Miss and Weak Q2 Outlook
Krispy Kreme (NASDAQ:DNUT) stock fell over 25% intra-day today after the company reported disappointing first-quarter results and issued guidance for the second quarter that fell well short of analyst expectations. The company posted a net loss of $33.4 million for the quarter. Adjusted earnings per...
May 8, 2025 4:26 PM - Davit Kirakosyan
Kenvue Beats Q1 Estimates, Adjusts Full-Year Outlook for Tariffs and Currency Headwinds
Kenvue (NYSE:KVUE) shares rose more than 5% intra-day today after the company delivered stronger-than-expected second-quarter results, but tempered its full-year outlook to reflect the impact of tariffs and currency pressures. The consumer health company reported adjusted earnings per share of $0.24...
May 8, 2025 4:24 PM - Davit Kirakosyan
Crocs Shares Rise 10% on Q1 Beat, Pulls 2025 Forecast Amid Global Trade Uncertainty
Crocs (NASDAQ:CROX) delivered a strong first-quarter performance, beating Wall Street expectations on both earnings and revenue, with shares rising over 10% intra-day today. The company reported adjusted earnings of $3.00 per share, well ahead of the $2.49 analyst forecast. Revenue climbed to $937 m...
May 8, 2025 4:21 PM - Davit Kirakosyan
ConocoPhillips Beats Q1 Estimates, Lowers Full-Year Spending Forecasts
ConocoPhillips (NYSE:COP) delivered first-quarter earnings that topped Wall Street expectations and trimmed its full-year spending plans, signaling strong operational discipline in the face of ongoing market volatility. Shares rose 5% intra-day today following the announcement. The company reported ...
May 8, 2025 4:19 PM - Davit Kirakosyan
Anheuser-Busch Tops Q1 Estimates as South America Strength Offsets Weak U.S. and China
Anheuser-Busch InBev (NYSE:BUD) delivered better-than-expected first-quarter results on Thursday, driven by robust growth in South America and reduced financing costs, helping to counter weaker performances in North America and China. The company reported revenue of $14.55 billion, reflecting 2.6% ...
May 8, 2025 2:06 PM - Gordon Thompson
TransCode Therapeutics, Inc. (RNAZ) Announces Reverse Stock Split
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) is a biotechnology company that specializes in developing RNA-based therapies for cancer treatment. The company is set to undergo a significant change on May 15, 2025, with a 1-for-28 reverse stock split. This move is intended to consolidate 28 shares into...
May 8, 2025 11:00 AM - Gordon Thompson
Papa John's International, Inc. (NASDAQ:PZZA) Overview and Financial Performance
Papa John's stock price target has seen a downward trend, but UBS analyst Dennis Geiger offers a notably higher price target of $93. The company reported Q4 earnings of $0.63 per share, surpassing the Zacks Consensus Estimate. Despite a recent 8.1% surge in stock price, the trend in earnings estim...
